Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,570.88
(0.44%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)

Island Pharmaceuticals Ltd

ILA

ASX

Island Pharmaceuticals Limited (ILA) is a mid-clinical stage biotechnology company and drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Company's lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases.

Latest Posts

Line Chart with Gradient
Price
$0.165
0 (0%)
At Close 22/11 (AEST)
Related Companies
BPH GLOBAL LTD
$BP8DD
ARGENICA THERAPEUTICS LIMITED
$AGN
PYC THERAPEUTICS LIMITED
$PYC
STARPHARMA HOLDINGS LIMITED
$SPL
IMMUTEP LIMITED
$IMM

Leave a Comment on ILA


Comments for ILA

    Latest Posts

    island-pharmaceuticals-asx-ila-doses-phase-2a-subjects-in-dengue-fever-trial-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) doses phase 2a subjects in dengue fever trial

    Phase 2a/b PROTECT clinical trial progresses with dosing of prophylactic arm subjects

    October 3, 2024
    island-pharmaceuticals-asx-ila-secures-funding-for-clinical-trials-and-pipeline-expansion-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) secures funding for clinical trials and pipeline expansion

    Firm commitments received for A$3.5m placement at A$0.07 per share to support clinical pipeline and due diligence for antiviral therapeutic

    October 3, 2024
    island-pharmaceuticals-asx-ila-requests-trading-halt-for-capital-raise-announcement-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) requests trading halt for capital raise announcement

    Trading halt requested to manage disclosure obligations and maintain orderly market

    October 1, 2024
    island-pharmaceuticals-asx-ila-executes-binding-letter-of-intent-for-proposed-acquisition-of-galidesivir-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) executes binding letter of intent for proposed acquisition of galidesivir

    Island Pharmaceuticals secures exclusive rights to acquire antiviral molecule galidesivir from BioCryst Pharmaceuticals

    September 11, 2024
    island-pharmaceuticals-asx-ila-reports-positive-data-from-isla-101-study-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) reports positive data from ISLA-101 study

    Reconfirms strong safety and pharmacokinetic data for Phase 2a clinical trial in dengue fever

    August 21, 2024
    island-pharmaceuticals-asx-ila-progresses-isla-101-phase-2a-b-clinical-trial-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) progresses ISLA-101 phase 2a/b clinical trial

    Progress update on PROTECT Phase 2a/b study for dengue fever treatment

    August 7, 2024
    island-pharmaceuticals-asx-ila-signs-non-binding-term-sheet-with-biocryst-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) signs non-binding term sheet with BioCryst

    Acquires antiviral molecule galidesivir to diversify pipeline

    July 4, 2024
    island-pharmaceuticals-asx-ila-reinstates-options-to-quotation-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) reinstates options to quotation

    Options of ILA reinstated to quotation by ASX Compliance

    April 2, 2024
    island-pharmaceuticals-asx-ila-announces-rights-issue-to-raise-1-95-million-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) announces rights issue to raise $1.95 million

    Capital raising to advance ISLA-101 for dengue fever treatment

    February 26, 2024
    island-pharmaceuticals-asx-ila-offers-non-renounceable-pro-rata-shares-and-options-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) offers non-renounceable pro rata shares and options

    Aims to raise $1.95 million for clinical trials, IP, and business development

    February 26, 2024
    island-pharmaceuticals-asx-ila-progresses-isla-101-single-ascending-dose-study-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) progresses ISLA-101 Single Ascending Dose study

    Company advances ISLA-101 study for dengue fever prevention

    February 26, 2024
    island-pharmaceuticals-asx-ila-progresses-isla-101-study-and-secures-key-patent-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) progresses ISLA-101 study and secures key patent

    Completes dosing cohorts, secures patent, and secures R&D Tax Incentive prepayment

    January 31, 2024
    island-pharmaceuticals-asx-ila-doses-third-cohort-in-isla-101-study-ila
    Health Care $ILA

    Island Pharmaceuticals (ASX: $ILA) doses third cohort in ISLA-101 study

    Third cohort dosed under fasted conditions, on track to report trial data in early 2024

    January 19, 2024

    ILA

    $ILA

    Island Pharmaceuticals (ASX: $ILA) progresses ISLA-101 Single Ascending Dose study

    Company advances ISLA-101 study for dengue fever prevention

    ILA

    $ILA

    Island Pharmaceuticals (ASX: $ILA) progresses ISLA-101 study and secures key patent

    Completes dosing cohorts, secures patent, and secures R&D Tax Incentive prepayment

    ILA

    $ILA

    Island Pharmaceuticals (ASX: $ILA) doses third cohort in ISLA-101 study

    Third cohort dosed under fasted conditions, on track to report trial data in early 2024

    Load More
    No More Posts
    Related Companies
    ANATARA LIFESCIENCES LTD
    $ANR
    GENETIC TECHNOLOGIES LIMITED
    $GTG
    DIMERIX LIMITED
    $DXB
    WELLFULLY LIMITED
    $WFL
    ACTINOGEN MEDICAL LIMITED
    $ACWNB

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions